118 related articles for article (PubMed ID: 19762400)
1. Digital vasculitis in systemic lupus erythematosus: a minor manifestation of disease activity?
Gomes C; Carvalho JF; Borba EF; Borges CT; Vendramini MB; Bueno C; Costa LP; Bonfá E
Lupus; 2009 Oct; 18(11):990-3. PubMed ID: 19762400
[TBL] [Abstract][Full Text] [Related]
2. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?
de Carvalho JF; Borba EF; Viana VS; Bueno C; Leon EP; Bonfá E
Arthritis Rheum; 2004 Nov; 50(11):3610-5. PubMed ID: 15529371
[TBL] [Abstract][Full Text] [Related]
3. Initial digital vasculitis in a large multicenter cohort of childhood-onset systemic lupus erythematosus.
Sakamoto AP; Silva CA; Silva MFCD; Lopes AS; Russo GCS; Sallum AME; Kozu K; Bonfá E; Saad-Magalhães C; Pereira RMR; Len CA; Terreri MT
Rev Bras Reumatol Engl Ed; 2017; 57(6):583-589. PubMed ID: 29050884
[TBL] [Abstract][Full Text] [Related]
4. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
Mahmoud RA; El-Gendi HI; Ahmed HH
Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
[TBL] [Abstract][Full Text] [Related]
5. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
[TBL] [Abstract][Full Text] [Related]
6. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
[TBL] [Abstract][Full Text] [Related]
7. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
8. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome.
Figueredo MA; Rodriguez A; Ruiz-Yagüe M; Romero M; Fernandez-Cruz A; Gomez-de la Concha E; Patiño R
J Rheumatol; 2006 Oct; 33(10):1980-6. PubMed ID: 17014014
[TBL] [Abstract][Full Text] [Related]
10. Skin denervation and cutaneous vasculitis in systemic lupus erythematosus.
Tseng MT; Hsieh SC; Shun CT; Lee KL; Pan CL; Lin WM; Lin YH; Yu CL; Hsieh ST
Brain; 2006 Apr; 129(Pt 4):977-85. PubMed ID: 16415307
[TBL] [Abstract][Full Text] [Related]
11. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
12. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
[TBL] [Abstract][Full Text] [Related]
13. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity.
Cook RJ; Gladman DD; Pericak D; Urowitz MB
J Rheumatol; 2000 Aug; 27(8):1892-5. PubMed ID: 10955329
[TBL] [Abstract][Full Text] [Related]
14. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.
Vilá LM; Alarcón GS; McGwin G; Friedman AW; Baethge BA; Bastian HM; Fessler BJ; Reveille JD;
Rheumatology (Oxford); 2004 Mar; 43(3):358-63. PubMed ID: 14623949
[TBL] [Abstract][Full Text] [Related]
15. Effect of severe neuropsychiatric manifestations on short-term damage in systemic lupus erythematosus.
Fragoso-Loyo HE; Sánchez-Guerrero J
J Rheumatol; 2007 Jan; 34(1):76-80. PubMed ID: 17143970
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
Heshmat NM; El-Kerdany TH
Pediatr Allergy Immunol; 2007 Jun; 18(4):346-53. PubMed ID: 17346298
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus disease activity index 2000.
Gladman DD; Ibañez D; Urowitz MB
J Rheumatol; 2002 Feb; 29(2):288-91. PubMed ID: 11838846
[TBL] [Abstract][Full Text] [Related]
20. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.
Jacobi AM; Odendahl M; Reiter K; Bruns A; Burmester GR; Radbruch A; Valet G; Lipsky PE; Dörner T
Arthritis Rheum; 2003 May; 48(5):1332-42. PubMed ID: 12746906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]